Projects per year
Personal profile
Biography
Chrishan is a NHMRC Senior Research Fellow and Head of the Fibrosis Laboratory, Department of Pharmacology at Monash. Having been trained as a matrix biologist, his research is focused on identifying novel therapeutic targets and more direct and potent treatment strategies for fibrosis (organ scarring) prevention; particularly associated with cardiovascular, renal and allergic airways diseases. Chrishan's main interest has been to establish the anti-fibrotic and therapeutic potential of the naturally occurring hormone, relaxin. He additionally investigates other novel anti-fibrotics and repair factors, as well as combination therapies that may aid in tissue repair and regeneration, in collaboration with others.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Fibrosis
- Cardiovascular disease
- Kidney Disease
- Lung Disease
- Stem Cell Biology
Network
-
MediBeacon Transdermal Mini Fluorophore Monitors
Colafella, K., Denton, K., Bubb, K., Cowley, M., Widdop, R., Lyras, D., Samuel, C., Bertram, J. & Parkington, H.
1/10/21 → 31/12/22
Project: Research
-
Pharmacological inhibition of IRAP as a novel antifibrotic strategy
Widdop, R., Samuel, C., Burrell, L. M., Chai, S. & Gaspari, T.
1/01/18 → 31/12/22
Project: Research
-
Evaluating the therapeutic effects of Cynata-MSCs in a murine model of pulmonary fibrosis
4/03/20 → 30/09/20
Project: Research
-
Preclinical rodent models of cardiac fibrosis
Wang, Y., Wang, M., Samuel, C. S. & Widdop, R. E., Mar 2022, In: British Journal of Pharmacology. 179, 5, p. 882-899 18 p.Research output: Contribution to journal › Review Article › Research › peer-review
1 Citation (Scopus) -
Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform
Bhuiyan, S., Shen, M., Chelvaretnam, S., Tan, A. Y., Ho, G., Hossain, M. A., Widdop, R. E. & Samuel, C. S., May 2021, In: The FASEB Journal. 35, 5, 16 p., e21595.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
Atrial Fibrillation and Obesity: Reverse Remodeling of Atrial Substrate With Weight Reduction
Mahajan, R., Lau, D. H., Brooks, A. G., Shipp, N. J., Wood, J. P. M., Manavis, J., Samuel, C. S., Patel, K. P., Finnie, J. W., Alasady, M., Kalman, J. M. & Sanders, P., May 2021, In: JACC: Clinical Electrophysiology. 7, 5, p. 630-641 12 p.Research output: Contribution to journal › Article › Research › peer-review
9 Citations (Scopus) -
Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/salt-induced hypertension
Li, Y., Shen, M., Ferens, D., Broughton, B. R. S., Murthi, P., Saini, S., Widdop, R. E., Ricardo, S. D., Pinar, A. A. & Samuel, C. S., Mar 2021, In: British Journal of Pharmacology. 178, 5, p. 1164-1181 18 p.Research output: Contribution to journal › Article › Research › peer-review
5 Citations (Scopus) -
Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice
Li, Y., Chakraborty, A., Broughton, B. R. S., Ferens, D., Widdop, R. E., Ricardo, S. D. & Samuel, C. S., Dec 2021, In: Biomedicine & Pharmacotherapy. 144, 12 p., 112256.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Citations (Scopus)